ArticleMolecules (Basel, Switzerland)2019
Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 97 citations in OpenAlex.
- A comparative study of the efficacy of apitoxin gel versus photobiomodulation by diode laser for recurrent aphthous stomatitis treatment.Journal of Taibah University Medical Sciences · 2026Article
- Sea nettle jellyfish venom targets proteoglycans to cause cell death and pain.Science advances · 2026Article
- Mechanisms of In Vitro Cytotoxicity of Honeybee Venom Components and Melittin-Functionalized FeMaterials (Basel, Switzerland) · 2026Article
- From Toxin to Therapy: Biomedical Applications of Bee Venom in Cancer, Diabetes, and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- Targeting Peptidergic Systems for Melanoma Treatment.Cancers · 2026Review
- Concentration-Dependent Anticancer Effects of Melittin-Functionalized Nanomaterials.Materials (Basel, Switzerland) · 2026Review
- Arthropod venom peptides: Pioneering nanotechnology in cancer treatment and drug delivery.Cancer pathogenesis and therapy · 2026Review
- Article
- FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells.Scientific reports · 2026Article
- AnCurrent medicinal chemistry · 2026Article
- Curcumin induces ferroptosis in ovarian cancer cells through the Nrf2/GPX4 regulation axis.American journal of cancer research · 2026Article
- Functional reprogramming of melittin by PluronicFrontiers in oncology · 2026Article
- Bee venom and thymoquinone combination inhibits cancer cells by inducing cell cycle arrest and apoptosis.Scientific reports · 2025Article
- Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025Article
- Antimicrobial Potential of Bee-Derived Products: Insights into Honey, Propolis and Bee Venom.Pathogens (Basel, Switzerland) · 2025Review
- Melittin-Based Nanoparticles for Cancer Therapy: Mechanisms, Applications, and Future Perspectives.Pharmaceutics · 2025Review
- Invertebrate venoms: A treasure trove of bioactive compounds with anticancer potential.Archives of toxicology · 2025Review
- The Invertebrate-Derived Antimicrobial Peptide Cm-p5 Induces Cell Death and ROS Production in Melanoma Cells.Marine drugs · 2025Article
- A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights.Inflammopharmacology · 2025Review
- Research progress on peptides that inhibit melanin synthesis.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Malignant melanoma is the deadliest form of skin cancer and highly chemoresistant. Melittin, an amphiphilic peptide containing 26 amino acid residues, is the major active ingredient from bee venom (BV). Although melittin is known to have several biological activities such as anti-inflammatory, antibacterial and anticancer effects, its antimelanoma effect and underlying molecular mechanism have not been fully elucidated. In the current study, we investigated the inhibitory effect and action mechanism of BV and melittin against various melanoma cells including B16F10, A375SM and SK-MEL-28. BV and melittin potently suppressed the growth, clonogenic survival, migration and invasion of melanoma cells. They also reduced the melanin formation in α-melanocyte-stimulating hormone (MSH)-stimulated melanoma cells. Furthermore, BV and melittin induced the apoptosis of melanoma cells by enhancing the activities of caspase-3 and -9. In addition, we demonstrated that the antimelanoma effect of BV and melittin is associated with the downregulation of PI3K/AKT/mTOR and MAPK signaling pathways. We also found that the combination of melittin with the chemotherapeutic agent temozolomide (TMZ) significantly increases the inhibition of growth as well as invasion in melanoma cells compared to melittin or TMZ alone. Taken together, these results suggest that melittin could be potentially applied for the prevention and treatment of malignant melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.